APG Asset Management N.V. Has $489,000 Position in United Therapeutics Corporation $UTHR

Key Points

• APG Asset Management N.V. reduced its stake in United Therapeutics Corporation by 32.6% to 1,715 shares, valued at approximately $489,000.
• Multiple institutional investors, including Allianz Asset Management and LPL Financial, have significantly increased their positions in United Therapeutics, indicating strong interest in the biotechnology company.
• Wall Street analysts have varying price targets for the stock, with a consensus target price of $382.00 and a rating of "Moderate Buy", despite the company's recent earnings miss.

APG Asset Management N.V. lowered its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 32.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,715 shares of the biotechnology company's stock after selling 830 shares during the period. APG Asset Management N.V.'s holdings in United Therapeutics were worth $489,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. XTX Topco Ltd acquired a new stake in shares of United Therapeutics in the first quarter valued at approximately $313,000. Allianz Asset Management GmbH increased its holdings in shares of United Therapeutics by 96.9% in the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock valued at $20,832,000 after purchasing an additional 33,254 shares in the last quarter. LPL Financial LLC increased its holdings in shares of United Therapeutics by 77.3% in the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock valued at $7,783,000 after purchasing an additional 11,007 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of United Therapeutics by 11.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after purchasing an additional 376 shares in the last quarter. Finally, Concurrent Investment Advisors LLC acquired a new stake in shares of United Therapeutics in the first quarter valued at approximately $227,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on UTHR. HC Wainwright set a $400.00 price objective on shares of United Therapeutics and gave the company a "buy" rating in a research note on Thursday, July 31st. Morgan Stanley reduced their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. Bank of America reduced their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. UBS Group raised their price objective on shares of United Therapeutics from $385.00 to $415.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 8th. Nine analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $382.00.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total value of $3,396,250.00. Following the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $11,356,133.75. The trade was a 23.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 12,000 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the sale, the chief financial officer directly owned 8,118 shares in the company, valued at $2,641,353.66. This represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,681 shares of company stock valued at $24,537,839. 10.30% of the stock is owned by insiders.

United Therapeutics Stock Down 1.3%

Shares of NASDAQ UTHR opened at $305.35 on Thursday. The company's fifty day moving average is $298.07 and its 200-day moving average is $306.73. The stock has a market cap of $13.77 billion, a price-to-earnings ratio of 11.92, a P/E/G ratio of 4.69 and a beta of 0.57. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The firm had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company's revenue for the quarter was up 11.7% compared to the same quarter last year. During the same period in the prior year, the business earned $5.85 earnings per share. On average, research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.